Results 41 to 50 of about 350,788 (241)

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients [PDF]

, 2009
<b>Purpose</b>: The expression and activation of the Ras/Raf-1/mitogen-activated protein kinase (MAPK) pathway plays an important role in the development and progression of cancer, and may influence response to treatments such as tamoxifen ...
Bartlett, J.M.S., Cameron, D., Cooke, T.G., Edwards, J., Kirkegaard, T., McGlynn, L.M., Tovey, S., Twelves, C.   +7 more
core   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours [PDF]

, 2009
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group.
A Ranganathan, BB Rasmussen, D Slamon, DJ Slamon, E A Mallon, EH Romond, H Joensuu, I Smith, J Bartlett, J C Doughty, J Edwards, J Richner, M Schmidt, M Untch, MF Press, N Harbeck, N Quenel, O-P Kallioniemi, PP Rosen, R Rakkhit, S Brown, S Chia, S M Tovey, S Paik, S Paik, S-S Ko, T G Cooke   +26 more
core   +2 more sources

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study [PDF]

, 2019
BACKGROUND: Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC.
Gbolahan, Olumide B., O’Neil, Bert, Sehdev, Amikar, Shahda, Safi, Tong, Yan   +4 more
core   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature [PDF]

, 2018
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment.
Berrios J. R. G., Bianco V., Caffarena G., Caporlingua A., Caporlingua F., Di Palma A., Fusto C., Magliocca F. M., Pecorari S., Prelaj A., Rebuzzi S. E., Salvati M., Tomao S.   +12 more
core   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source